FundedIQ
Biotechnology

CirculoGene Theranostics: Funding, Investors & Team (Sep 2026)

CirculoGene is a company in the biotechnology industry that has expertise in the areas of cfDNA, tumor monitoring, laboratory testing, molecular diagnostics and liquid biopsy. The lab they developed for cfDNA, cRNA, and MSI liquid biopsies is unique to them. CIRCULOGENE, their proprietary test is a next-generation sequencing process that can analyze a full genomic load from one standard tube of blood within one week. This technology is beneficial because it allows clinicians and their patients to make informed decisions about targeted therapies, monitor effectiveness and anticipate any possible relapse. They were established in 2015 and their headquarters are located in Birmingham, Alabama.

www.circulogene.com LinkedIn Birmingham, United States 11-50 employees
Biotechnology Genetics Therapeutics Cfdna Liquid biopsy Tumor monitoring Laboratory testing Molecular diagnostics
Total raised
$2.8M
Rounds
2
Latest
Undisclosed round
Mar 2023

CirculoGene Theranostics has raised $2.8M across 2 funding rounds on record, the most recent an undisclosed round of $2.0M announced in Mar 2023.

That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

CirculoGene Theranostics Company Profile and Key Stats

Total funding raised
$2.8M
across 2 rounds on record
Funding rounds on record
2
Latest funding round
Undisclosed round
$2.0M in Mar 2023
Employees
11-50
reported band
Headquarters
Birmingham, United States

Latest funding round on record: Mar 2023.

CirculoGene Theranostics Funding Rounds

Date
Round
Amount
Undisclosed round
$2.0M
Debt Financing
$750k

CirculoGene Theranostics raised $750k in a Debt Financing announced in Aug 2022.

7 months later, an undisclosed round of $2.0M was announced in Mar 2023.

CirculoGene Theranostics Founders and Leadership Team

Name
Role
Contact
Chen Hsiung Yeh
Founder
Michael Mullen
CEO

No contact details are on record for this team yet.

CirculoGene Theranostics Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M

CirculoGene Theranostics' latest round of $2.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like CirculoGene Theranostics in Biotechnology and Birmingham

Companies Similar to CirculoGene Theranostics

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

CirculoGene Theranostics Funding FAQs

What does CirculoGene Theranostics do?

CirculoGene is a company in the biotechnology industry that has expertise in the areas of cfDNA, tumor monitoring, laboratory testing, molecular diagnostics and liquid biopsy. The lab they developed for cfDNA, cRNA, and MSI liquid biopsies is unique to them. CIRCULOGENE, their proprietary test is a next-generation sequencing process that can analyze a full genomic load from one standard tube of blood within one week. This technology is beneficial because it allows clinicians and their patients to make informed decisions about targeted therapies, monitor effectiveness and anticipate any possible relapse. They were established in 2015 and their headquarters are located in Birmingham, Alabama.

How much funding has CirculoGene Theranostics raised?

CirculoGene Theranostics has raised $2.8M across 2 rounds on record. The most recent is an undisclosed round of $2.0M announced in Mar 2023.

When did CirculoGene Theranostics last raise funding?

CirculoGene Theranostics' most recent funding round on record is an undisclosed round of $2.0M, announced in Mar 2023.

Who founded CirculoGene Theranostics?

FundedIQ lists Chen Hsiung Yeh (Founder) at CirculoGene Theranostics.

Who is the CEO of CirculoGene Theranostics?

Michael Mullen is listed as CEO at CirculoGene Theranostics.

Where is CirculoGene Theranostics headquartered?

CirculoGene Theranostics is based in Birmingham, Alabama, United States.

How many employees does CirculoGene Theranostics have?

CirculoGene Theranostics is in the 11-50 employee band.

How does CirculoGene Theranostics' funding compare to other Biotechnology startups?

CirculoGene Theranostics' latest round of $2.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's CirculoGene Theranostics Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CirculoGene Theranostics is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.